These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36915628)

  • 1. The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations.
    Kagawa Y; Hayashida T; Liu J; Mori S; Izumi H; Kumagai S; Udagawa H; Hattori N; Goto K; Kobayashi SS
    JTO Clin Res Rep; 2023 Mar; 4(3):100462. PubMed ID: 36915628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
    Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.
    Kobayashi IS; Shaffer W; Viray H; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
    JTO Clin Res Rep; 2024 Jan; 5(1):100614. PubMed ID: 38229766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
    Hamada A; Suda K; Nishino M; Obata K; Oiki H; Fukami T; Fukuda S; Fujino T; Ohara S; Koga T; Chiba M; Shimoji M; Ito M; Takemoto T; Soh J; Tsutani Y; Mitsudomi T
    J Thorac Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 37666482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance.
    Nishino M; Suda K; Koga T; Ohara S; Fujino T; Soh J; Tirunagaru V; Vellanki A; Doebele RC; Mitsudomi T
    Thorac Cancer; 2021 May; 12(10):1511-1516. PubMed ID: 33710795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.
    Vasconcelos PENS; Gergis C; Viray H; Varkaris A; Fujii M; Rangachari D; VanderLaan PA; Kobayashi IS; Kobayashi SS; Costa DB
    JTO Clin Res Rep; 2020 Sep; 1(3):. PubMed ID: 34104899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.
    Hasako S; Terasaka M; Abe N; Uno T; Ohsawa H; Hashimoto A; Fujita R; Tanaka K; Okayama T; Wadhwa R; Miyadera K; Aoyagi Y; Yonekura K; Matsuo K
    Mol Cancer Ther; 2018 Aug; 17(8):1648-1658. PubMed ID: 29748209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple
    Zheng Q; Chen D; Wang X; Yang Y; Zhao S; Dong X; Ma C; Zhang X; Duan H; Sun Y; Zheng S
    Ann Transl Med; 2022 Jun; 10(12):696. PubMed ID: 35845484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.
    Kobayashi Y; Fujino T; Nishino M; Koga T; Chiba M; Sesumi Y; Ohara S; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    J Thorac Oncol; 2018 May; 13(5):727-731. PubMed ID: 29410323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.
    Kobayashi Y; Azuma K; Nagai H; Kim YH; Togashi Y; Sesumi Y; Chiba M; Shimoji M; Sato K; Tomizawa K; Takemoto T; Nishio K; Mitsudomi T
    Mol Cancer Ther; 2017 Feb; 16(2):357-364. PubMed ID: 27913578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant
    Udagawa H; Hasako S; Ohashi A; Fujioka R; Hakozaki Y; Shibuya M; Abe N; Komori T; Haruma T; Terasaka M; Fujita R; Hashimoto A; Funabashi K; Yasuda H; Miyadera K; Goto K; Costa DB; Kobayashi SS
    Mol Cancer Res; 2019 Nov; 17(11):2233-2243. PubMed ID: 31467113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
    Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
    Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.
    Yonesaka K; Kobayashi Y; Hayashi H; Chiba Y; Mitsudomi T; Nakagawa K
    Oncol Rep; 2019 Feb; 41(2):1059-1066. PubMed ID: 30483795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.
    Lin YT; Liu YN; Wu SG; Yang JC; Shih JY
    Clin Lung Cancer; 2017 May; 18(3):324-332.e1. PubMed ID: 28089594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.
    Grabe T; Jeyakumar K; Niggenaber J; Schulz T; Koska S; Kleinbölting S; Beck ME; Müller MP; Rauh D
    ACS Med Chem Lett; 2023 May; 14(5):591-598. PubMed ID: 37197473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model.
    Sarcar B; Gimbrone NT; Wright G; Remsing Rix LL; Gordian ER; Rix U; Chiappori AA; Reuther GW; Santiago-Cardona PG; Muñoz-Antonia T; Cress WD
    FEBS Open Bio; 2019 Oct; 9(10):1689-1704. PubMed ID: 31314158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations.
    Vasconcelos PENS; Kobayashi IS; Kobayashi SS; Costa DB
    JTO Clin Res Rep; 2021 Mar; 2(3):. PubMed ID: 33728415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study.
    Fukuda S; Suda K; Hamada A; Oiki H; Ohara S; Ito M; Soh J; Mitsudomi T; Tsutani Y
    Biomedicines; 2024 Jun; 12(7):. PubMed ID: 39061985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.